Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: A randomized, double-blind, placebo-controlled trial. - Wikidata - wikimedia - TriplyDB

Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: A randomized, double-blind, placebo-controlled trial.

Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: A randomized, double-blind, placebo-controlled trial.

http://www.wikidata.org/entity/Q44365732

about

Do vasopressin V2 receptor antagonists benefit cirrhotics with refractory ascites?Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials.Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis.Tolvaptan for the treatment of liver cirrhosis oedema.Diuretic usage for protection against end-organ damage in liver cirrhosis and heart failure.Treatment for cirrhotic ascites.Predictive parameter of tolvaptan effectiveness in cirrhotic ascites.Efficacy of peritoneovenous shunt for treating tolvaptan-resistant refractory ascites in a cirrhotic patient with portal vein thrombosis: A case report.Efficacy of tolvaptan in patients with refractory ascites in a clinical setting Safety and efficacy of long-term tolvaptan therapy for decompensated liver cirrhosis.Effects of low-dose tolvaptan on electrolyte abnormality and hemodynamic parameters in a liver cirrhosis-associated portopulmonary hypertension patient: A case report.Therapeutic effects of short- and intermediate-term tolvaptan administration for refractory ascites in patients with advanced liver cirrhosis.Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: A randomized study.Approach to hyponatremia according to the clinical setting: Consensus statement from the Italian Society of Endocrinology (SIE), Italian Society of Nephrology (SIN), and Italian Association of Medical Oncology (AIOM).Effectiveness and safety of tolvaptan in liver cirrhosis patients with edema: Interim results of post-marketing surveillance of tolvaptan in liver cirrhosis (START study).Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites.Management of refractory cirrhotic ascites: challenges and solutions

P2860

Q26778032-136E730A-590B-42B0-ABAA-B58B4DD6A915 Q34093932-020D6021-C0DA-4C8A-AC05-7F2504881432 Q35092574-95DF42F8-5F03-4475-AD24-B0DB0BBC27E1 Q35657152-5F8AAE33-7AEA-44FB-9075-C73FE7B04AA2 Q36118182-E190E65C-3696-4863-8731-5F9D4A813272 Q37414345-94DC684D-E4B2-4657-8741-29FC67C90C58 Q38200108-AD127F5C-D2FA-4590-BA8D-50838EEC2FA0 Q38779628-7002D6AC-D64A-4273-B862-7239AB9EB13F Q38882366-4235134E-2091-40C8-82E9-74BC991FC790 Q39321625-133D3E5F-B781-44A5-9EE8-D814B2D44F4D Q40496089-42B3C306-9F45-46F7-877D-D0E4D5266C3B Q40771170-90E0198E-A8D5-4E10-A1C9-286AB820C24F Q40783974-C2CA545E-D1E8-407D-8484-77EF1CC07196 Q42329743-5163B4F0-BD86-45CC-B765-D49C69C300EA Q45853525-E254723F-B86A-480B-86E0-6F1F120B99B7 Q47280183-3ED6152B-BC96-4A98-BF0F-12249F4B21B3 Q49893436-553CDCA1-B79C-475A-B958-CBAFCDF8CE07 Q50221452-68092E8C-877B-4735-983C-62CE249BBCBA Q50277167-F2B42610-B1D1-48E4-A981-67231C43EF02 Q57407557-8C930030-14F7-4EC0-AEAA-7C999D8E8F0B

P2860

Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: A randomized, double-blind, placebo-controlled trial.

http://www.wikidata.org/entity/Q44365732

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Dose-finding trial of tolvapta ...... ind, placebo-controlled trial.

@en

Dose-finding trial of tolvapta ...... ind, placebo-controlled trial.

@nl

type

label

Dose-finding trial of tolvapta ...... ind, placebo-controlled trial.

@en

Dose-finding trial of tolvapta ...... ind, placebo-controlled trial.

@nl

prefLabel

Dose-finding trial of tolvapta ...... ind, placebo-controlled trial.

@en

Dose-finding trial of tolvapta ...... ind, placebo-controlled trial.

@nl

P1433

Q44365732-267BBF32-6F1D-4213-A957-BE821B9318F0

P1476

Q44365732-77D0A997-2A74-46EB-9436-3ECF8D6046D4

P2093

Q44365732-164B88BE-3524-45E8-8726-370917EE2E02

Q44365732-219BB600-5740-4D76-B02F-F04627817FF9

Q44365732-28EEDC70-E80E-48E1-A5C2-A32A5489FD49

Q44365732-34A5CE48-B384-433E-9CC6-C4DD36AA727B

Q44365732-4FA83AF6-4C7E-4E78-BB1D-4EF1B84955A4

Q44365732-C3D0D40C-260E-4C06-91A5-DAF430165D55

Q44365732-DFDFA138-A0F9-4116-BD7C-10955E9CAFCA

Q44365732-E2C25990-5AD2-4750-8DDB-FFC9402D5128

P2860

Q44365732-07F63265-8DF5-4825-84FD-CEFA866AE4E3

Q44365732-13179F35-BA9E-486D-AB33-FB2208C6CBF8

Q44365732-1DD0A6E8-860B-4432-AD08-4864C6F1BD23

Q44365732-224D9E74-F586-40C7-A5D5-3EBD83F44723

Q44365732-288505B4-1E2C-41B1-A717-BC1F97365D93

Q44365732-2A23E413-F5D8-47F7-BF03-E0D45F7E47B2

Q44365732-309C6C51-6BA9-49AD-9336-39BDEDE84646

Q44365732-31B03554-81A8-42FA-B570-DD229F28C8AB

Q44365732-38229497-9513-4102-AD80-DA5D8D0B149A

Q44365732-40C677BC-F897-4A7D-8F14-16A723A4DFA4

P304

Q44365732-35C9856F-8AAD-427C-AAA0-6B39DBDC532F

P31

Q44365732-21441AC1-30B2-49B7-B315-D05550A83068

P356

Q44365732-AF68AED0-B8C9-4F39-9BBA-E15940D5D7EE

P433

Q44365732-BDF6F26D-3DB3-4DD5-BA8A-5B80A87B5875

P478

Q44365732-A22121C8-6BB2-4035-9182-78411A462B67

P577

Q44365732-03AC46A8-FBAD-46C1-BD68-8F0903B015C6

P5875

Q44365732-7D1A1307-760A-4C02-BC53-D05B259E02CB

P698

Q44365732-257BE39E-9693-44AE-B5FF-E239446D1C06

P921

Q44365732-AB5B3D8B-E0AE-4C91-905B-62982BEA65A4

Q44365732-B22E7111-5138-42B7-866A-4ADAE00BA070

P356

P1433

Hepatology Research

P1476

Dose-finding trial of tolvapta ...... ind, placebo-controlled trial.

@en

P2093

ASCITES Dose-Finding Trial Group

http://www.w3.org/2001/XMLSchema#string

Akira Kaneko

http://www.w3.org/2001/XMLSchema#string

Chitomi Hasebe

http://www.w3.org/2001/XMLSchema#string

Isao Sakaida

http://www.w3.org/2001/XMLSchema#string

Kiwamu Okita

http://www.w3.org/2001/XMLSchema#string

Kozo Kajimura

http://www.w3.org/2001/XMLSchema#string

Mitsuru Okada

http://www.w3.org/2001/XMLSchema#string

Seiji Kawazoe

http://www.w3.org/2001/XMLSchema#string

P2860

Management of cirrhosis and ascites.

Liver cirrhosis

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.

High relative fat-free mass is important for maintaining serum albumin levels in patients with compensated liver cirrhosis

Non-peptide arginine-vasopressin antagonists: the vaptans.

Diuretic strategies in patients with acute decompensated heart failure.

Tolvaptan: a selective vasopressin type 2 receptor antagonist in congestive heart failure.

Evaluation and management of patients with refractory ascites.

EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.

Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH).

P304

83-91

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/HEPR.12099

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236082614

http://www.w3.org/2001/XMLSchema#string

P698

23530991

http://www.w3.org/2001/XMLSchema#string

P921

liver cirrhosis